Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07784374 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Aug 31, 2026 to Aug 20, 2026 · Eligibility criteria expanded, about 16 words · Secondary endpoints: 13 to 10 · 2 more Show 5 more changesShow less
    • Start date changed from estimate of Aug 31, 2026 to Aug 20, 2026
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: 13 to 10
    • Site details revised
    • Study title shortened, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2 study. All subjects are patients with locally advanced unresectable or metastatic pancreatic cancer harboring KRAS G12D mutation who have received at least one prior line of systemic therapy. The purpose of this study is to evaluate the anti-tumor efficacy of GFH375 plus GFH276 versus GFH375 monotherapy, and to assess the impact of GFH375 plus GFS202A versus GFH375 monotherapy on patient body weight.
Trial Details
NCT Number NCT07784374
Lead Sponsor Genfleet Therapeutics (Shanghai) Inc.
Conditions Pancreatic Cancer
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov